CLARITY PHARMACEUTICALS Trademark

Trademark Overview


On Wednesday, July 10, 2024, a trademark application was filed for CLARITY PHARMACEUTICALS with the United States Patent and Trademark Office. The USPTO has given the CLARITY PHARMACEUTICALS trademark a serial number of 98641771. The federal status of this trademark filing is RESPONSE AFTER NON-FINAL ACTION - ENTERED as of Thursday, September 4, 2025. This trademark is owned by Clarity Pharmaceuticals Ltd. The CLARITY PHARMACEUTICALS trademark is filed in the Advertising, Business and Retail Services, Chemical Products, Pharmaceutical Products, Treatment & Processing of Materials Services, Medical Instrument Products, and Computer & Software Services & Scientific Services categories with the following description:

Custom manufacture of pharmaceuticals for the treatment, imaging, diagnosis and therapy of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, non-Hodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumours, blood-borne tumours, leukemia and melanoma; custom manufacture of radiopharmaceuticals; custom manufacture of radiopharmaceuticals for the treatment, imaging, diagnosis and therapy of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fa...

Pharmaceutical, medicinal, veterinary and therapeutic preparations and substances for theranostics being the use of radioisotopes for the diagnosis and treatment of cancers; radiopharmaceutical preparations for the treatment and diagnosis of cancers; radioprotectors, namely, drugs or compounds that reduce damage to healthy tissue caused by radiation in the course of the diagnosis and treatment of cancers; radiopharmaceuticals for use in theranostics, namely, imaging and detection agents for diagnosing and treating cancers; radiopharmaceutical products, namely, diagnostic and therapeutic radiopharmaceutical agents for use in PET imaging; radiopharmaceutical diagnostic and therapeutic preparations for medical purposes, namely, radiopharmaceuticals for medical and clinical use; radiopharmaceutical preparations and substances for use in oncology, namely radiopharmaceutical preparations for diagnosing and treating cancer; radiopharmaceutical preparations for the treatment of cancer; radio t...

Wholesale services featuring pharmaceuticals in the nature of radiopharmaceutical preparations for the treatment and diagnosis of cancers; import-exports agencies in the field of pharmaceuticals in the nature of radiopharmaceutical preparations for the treatment and diagnosis of cancers; promotion and advertising of products and services for the treatment of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, non-Hodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumours, bloodborne tumours, leukemia and melanoma, in the nature of radiopharmaceutical preparations; marketing...

Radioactive substances for scientific and commercial purposes, namely, radioactive elements for scientific purposes; radioactive elements and isotopes for industrial, scientific and research purposes; radioactive preparations for commercial purposes, namely nuclides and radionuclides, for use in radiographic techniques; radioactive elements for scientific purposes; radioactive preparations for scientific purposes; chemical products for radioactive labelling; radiodiagnostic in-vivo agent used for scientific purposes, namely, in-vivo diagnostic agent used for detection and monitoring of carcinogenesis and anti-carcinogenic therapy; radiochemical products for scientific purposes, namely, chemical products for biotechnological product development; radioactive materials for laboratory purposes, namely, radioactive elements, nuclides and radionuclides; radioactive materials for scientific purposes, namely, radioactive elements, nuclides and radionuclides

Radiotherapy apparatus and instruments; implantable radioactive sources of radiation, namely, implantable radiation therapy devices consisting of radioactive seeds with or without a bioabsorbable carrier assembly; insulated containers especially adapted for temperature sensitive products for medical use, namely, insulated containers especially designed for transporting and holding radiopharmaceuticals; radiation therapy equipment; radioisotope therapy apparatus for medical purposes; radio-oncological irradiation apparatus for medical purposes; radio-oncological irradiation instruments for medical purposes; linear accelerator for medical purposes in radiotherapy; apparatus and instruments for radioisotopic therapy; radiation therapy instruments for medical purposes; medical devices for use in treating or diagnosing cancers including via radiotherapy; cancer irradiation apparatus for medical purposes; cancer irradiation instruments for medical purposes; pharmaceutical instruments, namely...

Pharmaceutical, medicinal, veterinary and therapeutic research and development in relation to radiopharmaceuticals for use in the imaging, diagnosis, treatment and therapy of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, non-Hodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumours, blood-borne tumours, leukemia and melanoma; scientific research in the nature of conducting clinical trials for others in relation to radiopharmaceuticals for use in the imaging, diagnosis, treatment and therapy of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, bra...
clarity pharmaceuticals

General Information


Serial Number98641771
Word MarkCLARITY PHARMACEUTICALS
Filing DateWednesday, July 10, 2024
Status661 - RESPONSE AFTER NON-FINAL ACTION - ENTERED
Status DateThursday, September 4, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesCustom manufacture of pharmaceuticals for the treatment, imaging, diagnosis and therapy of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, non-Hodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumours, blood-borne tumours, leukemia and melanoma; custom manufacture of radiopharmaceuticals; custom manufacture of radiopharmaceuticals for the treatment, imaging, diagnosis and therapy of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, non-Hodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumours, blood-borne tumours, leukemia and melanoma; providing information, consultancy and advisory services in relation to the aforementioned services
Goods and ServicesPharmaceutical, medicinal, veterinary and therapeutic preparations and substances for theranostics being the use of radioisotopes for the diagnosis and treatment of cancers; radiopharmaceutical preparations for the treatment and diagnosis of cancers; radioprotectors, namely, drugs or compounds that reduce damage to healthy tissue caused by radiation in the course of the diagnosis and treatment of cancers; radiopharmaceuticals for use in theranostics, namely, imaging and detection agents for diagnosing and treating cancers; radiopharmaceutical products, namely, diagnostic and therapeutic radiopharmaceutical agents for use in PET imaging; radiopharmaceutical diagnostic and therapeutic preparations for medical purposes, namely, radiopharmaceuticals for medical and clinical use; radiopharmaceutical preparations and substances for use in oncology, namely radiopharmaceutical preparations for diagnosing and treating cancer; radiopharmaceutical preparations for the treatment of cancer; radio therapeutic preparations, namely, radio-isotope markers for therapeutic or diagnostic use; chemical substances and preparations being radioactive substances for medical purposes; radioisotopes for medical purposes, namely, radio-isotope markers for therapeutic or diagnostic use; diagnostic and therapeutic radioisotopes and radiochemical preparations for medical purposes, namely, for the treatment of cancers; radiopharmaceutical preparations and substances for endoradionuclide therapy, brachytherapy; radiopharmaceuticals used in the field of nuclear medicine, medical imaging and therapy, namely diagnostic radiopharmaceutical agent for use in PET imaging; diagnostic radiopharmaceutical preparations and substances for positron emission tomography; diagnostic radiopharmaceutical preparations and substances for single photon emission tomography, target radionuclide and peptide receptor radionuclide therapy; pharmaceutical preparations in the field of oncology, namely, theranostics drugs for use in the treatment of cancer; pharmaceutical preparations in the field of precision oncology, namely, theranostics drugs for use in the treatment of cancer; radiopharmaceutical preparations for use in oncology, namely, radiopharmaceutical preparations containing radioisotopes for treatment and diagnosis of tumors; target radiopharmaceutical pharmaceuticals containing a target molecule for the treatment of cancers; pharmaceutical preparations for targeted radionuclide therapy; therapeutic agents for delivery of radioactive material to target sites within the body; irradiated or radioactive microspheres used for therapeutic medical purposes; radiopharmaceutical preparations for use in the imaging, diagnosis and therapy of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, non-Hodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumors, blood-borne tumors, leukemia and melanoma; radiopharmaceutical preparations containing radioisotopes with short half-lives for diagnostic applications; chemical preparations in the nature of radiopharmaceuticals for diagnostic uses; radiopharmaceuticals for use with highly sensitive molecular imaging technologies such as positron emission tomography or single photon emission tomography, for the production of images of organs and lesions and for the early diagnosis of diseases; radiopharmaceutical preparations containing medical radioisotopes with longer half-lives, for the treatment of tumour diseases; radiopharmaceutical drugs for diagnostic uses; radiopharmaceutical preparations for diagnostic uses; radio-isotope markers, isotopes, preparations and reagents for medical purposes for use in radioactive labelling of cancer cells; radioactive pharmaceuticals and non-radioactive reagents for producing radiopharmaceuticals for diagnosis or for therapeutic use; diagnostic scanning agents for medical use, namely, diagnostic scanning agents for in vivo use; positron emission tomography tracers for medical use, namely, radioactive isotopes used to label cancer cells; positron emission tomography tracers prepared for ingestion or injection into humans and animals, namely, radioactive isotopes used to label cancer cells; preparations for use in molecular imaging for medical use, namely, radioactive isotopes for in vivo imaging; Pharmaceutical preparations and diagnostic preparations for medical purposes, namely, radiotherapeutic preparations used in the application of radioisotopes and radiation in medicine, including nuclear medical diagnostics and therapy, oncologic diagnostics and therapy, hematologic diagnostics and therapy, radiologic diagnostics and therapy; Pharmaceutical preparations and diagnostic preparations for medical purposes, namely, radiodiagnostic preparations used in the application of radioisotopes and radiation in medicine, including nuclear medical diagnostics and therapy, oncologic diagnostics and therapy, hematologic diagnostics and therapy, radiologic diagnostics and therapy; radiopharmaceutical diagnostic preparations for medical use; radiopharmaceutical diagnostic preparations for use in the diagnosis of disease; radioactive marked substances for diagnostic purposes, namely, radio-isotope markers; diagnostic radiopharmaceutical preparations and radio-isotope markers for therapeutic purposes; pharmaceutical solutions for radioactive labelling; diagnostic imaging agents for magnetic resonance imaging
Goods and ServicesWholesale services featuring pharmaceuticals in the nature of radiopharmaceutical preparations for the treatment and diagnosis of cancers; import-exports agencies in the field of pharmaceuticals in the nature of radiopharmaceutical preparations for the treatment and diagnosis of cancers; promotion and advertising of products and services for the treatment of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, non-Hodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumours, bloodborne tumours, leukemia and melanoma, in the nature of radiopharmaceutical preparations; marketing of products and services for the treatment of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, non-Hodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumours, blood-borne tumours, leukemia and melanoma, in the nature of radiopharmaceutical preparations; business intermediary services for the sale and purchase of goods and services for the treatment of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, non-Hodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumours, blood-borne tumours, leukemia and melanoma, in the nature of radiopharmaceutical preparations; providing an on-line commercial information directory for products and services for the treatment of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, non-Hodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumours, blood-borne tumours, leukemia and melanoma, in the nature of radiopharmaceutical preparations; providing information, consultancy and advisory services in relation to the aforementioned services
Goods and ServicesRadioactive substances for scientific and commercial purposes, namely, radioactive elements for scientific purposes; radioactive elements and isotopes for industrial, scientific and research purposes; radioactive preparations for commercial purposes, namely nuclides and radionuclides, for use in radiographic techniques; radioactive elements for scientific purposes; radioactive preparations for scientific purposes; chemical products for radioactive labelling; radiodiagnostic in-vivo agent used for scientific purposes, namely, in-vivo diagnostic agent used for detection and monitoring of carcinogenesis and anti-carcinogenic therapy; radiochemical products for scientific purposes, namely, chemical products for biotechnological product development; radioactive materials for laboratory purposes, namely, radioactive elements, nuclides and radionuclides; radioactive materials for scientific purposes, namely, radioactive elements, nuclides and radionuclides
NOT AVAILABLE"PHARMACEUTICALS"
Goods and ServicesRadiotherapy apparatus and instruments; implantable radioactive sources of radiation, namely, implantable radiation therapy devices consisting of radioactive seeds with or without a bioabsorbable carrier assembly; insulated containers especially adapted for temperature sensitive products for medical use, namely, insulated containers especially designed for transporting and holding radiopharmaceuticals; radiation therapy equipment; radioisotope therapy apparatus for medical purposes; radio-oncological irradiation apparatus for medical purposes; radio-oncological irradiation instruments for medical purposes; linear accelerator for medical purposes in radiotherapy; apparatus and instruments for radioisotopic therapy; radiation therapy instruments for medical purposes; medical devices for use in treating or diagnosing cancers including via radiotherapy; cancer irradiation apparatus for medical purposes; cancer irradiation instruments for medical purposes; pharmaceutical instruments, namely, radiological apparatus for medical purposes for the treatment of cancer and diseases associated with cellular proliferation; medical apparatus for administering radiopharmaceutical diagnostic products; parts and fittings for the aforesaid goods
Goods and ServicesPharmaceutical, medicinal, veterinary and therapeutic research and development in relation to radiopharmaceuticals for use in the imaging, diagnosis, treatment and therapy of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, non-Hodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumours, blood-borne tumours, leukemia and melanoma; scientific research in the nature of conducting clinical trials for others in relation to radiopharmaceuticals for use in the imaging, diagnosis, treatment and therapy of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, non-Hodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumours, blood-borne tumours, leukemia and melanoma; scientific research and development in the field of radiopharmaceuticals and radioprotectors; scientific research and development in the field of theranostics; scientific research and development in the field of radioisotopes suitable for diagnostic and therapeutic medical use; scientific and technological services, namely, scientific research, analysis, testing, and research on radiopharmaceuticals for the diagnosis, therapy and treatment of diseases; engineering services in the field of radiopharmaceuticals and radioisotopes suitable for diagnostic and therapeutic and medical use; scientific research and development of radioisotopes suitable for radiopharmaceuticals; scientific research and development of new procedures and experiments for the discovery, identification or improvement of radioisotopes for radiopharmaceuticals; scientific research and development and engineering services in the field of radioisotopes, radioisotope generators, and linkers suitable for radiopharmaceuticals; scientific research and development in the isolation and capture of radioisotopes suitable for radiopharmaceuticals; scientific research in the nature of conducting clinical trials for others, namely, conducting phase clinical trials with target radiopharmaceuticals; medical research services relating to the development of radiotherapeutics and precision oncology; research, development and testing services relating to radiopharmaceuticals; radio labelling scientific research, namely, labelling of both small molecules and biologics; providing information, advisory and consultancy services in relation to the aforementioned services

Classification Information


International Class035 - Advertising; business management; business administration; office functions.
US Class Codes100, 101, 102
Class Status Code6 - Active
Class Status DateWednesday, July 10, 2024
Primary Code035
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class001 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins; unprocessed plastics; manures; fire extinguishing compositions; tempering and soldering preparations; chemical substances for preserving foodstuffs; tanning substances; adhesives used in industry.
US Class Codes001, 005, 006, 010, 026, 046
Class Status Code6 - Active
Class Status DateWednesday, July 10, 2024
Primary Code001
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, July 10, 2024
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class040 - Treatment of materials.
US Class Codes100, 103, 106
Class Status Code6 - Active
Class Status DateWednesday, July 10, 2024
Primary Code040
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class010 - Surgical, medical, dental, and veterinary apparatus and instruments, artificial limbs, eyes, and teeth; orthopedic articles; suture materials.
US Class Codes026, 039, 044
Class Status Code6 - Active
Class Status DateWednesday, July 10, 2024
Primary Code010
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateWednesday, July 10, 2024
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameClarity Pharmaceuticals Ltd
Party Type10 - Original Applicant
Legal Entity Type11 - Company
AddressEveleigh, NSW, 2015
AU

Trademark Events


Event DateEvent Description
Wednesday, July 10, 2024NEW APPLICATION ENTERED
Wednesday, July 10, 2024NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, December 30, 2024ASSIGNED TO EXAMINER
Thursday, January 30, 2025EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED
Thursday, January 30, 2025EXAMINERS AMENDMENT AND/OR PRIORITY ACTION - COMPLETED
Friday, April 11, 2025CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, April 11, 2025TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, January 30, 2025COMBINED EXAMINER'S AMENDMENT/PRIORITY ACTION AUTOMATIC ENTRY
Thursday, January 30, 2025NOTIFICATION OF EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED
Friday, April 11, 2025TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, June 9, 2025NON-FINAL ACTION E-MAILED
Monday, June 9, 2025NON-FINAL ACTION WRITTEN
Monday, June 9, 2025NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, September 4, 2025CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, September 4, 2025TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, September 4, 2025TEAS/EMAIL CORRESPONDENCE ENTERED